• 1
    De Vita V Jr., Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 5th ed. Philadelphia, New York: Lippincott-Raven; 1997: 951961.
  • 2
    Shin DM, Walsh GL, Komaki R, Putnam JB, Nesbitt J, Ro JY, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med. 1998; 129: 100104.
  • 3
    Cowen D, Hannoun-Levi JM, Resbeut M, et al. Natural history and treatment of malignant thymoma. Oncology. 1998; 12: 10011005.
  • 4
    Loehrer PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol. 1994; 12: 11641168.
  • 5
    Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, et al. Chemotherapy for invasive thymoma: a 13-year experience. Cancer. 1991; 68: 3033.
  • 6
    Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol. 1999; 17: 22802289.
  • 7
    Sandler A, Fox S, Meyers T, Christou A, Weber G, Gohin R, et al. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. Am J Clin Oncol. 1998; 21: 180184.
  • 8
    Jan N, Villani GM, Trambert J, et al. A novel second line chemotherapy treatment of recurrent thymoma. Med Oncol. 1997; 14: 163168.
  • 9
    Internet PDQ Clinical Trial Search on malignant thymoma (status of trial: closed). Available at: Accessed December 12, 2000.
  • 10
    Internet PDQ Clinical Trial Search on malignant thymoma (status of trial: open). Available at: Accessed December 12, 2000.
  • 11
    Fuller PJ, Verity K. Somatostatin gene expression in the thymus gland. J Immunol. 1989; 143: 10151017.
  • 12
    Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SWJ, Gebbers J-O, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993; 82: 21432151.
  • 13
    Reubi JC, Horisberger U, Kappeler A, Laissue JA. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood. 1998; 92: 191197.
  • 14
    Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, et al. In vivo detection of malignant thymic masses by indium-111-DTPA-d-Phe1-octreotide scintigraphy. J Nucl Med. 1998; 39: 634639.
  • 15
    Palmieri G, Lastoria S, Colao A, Vergara E, Varrella P, Biondi E, et al. Successful treatment of a patient with a thymoma and pure-red cell aplasia with octreotide and prednisone. N Engl J Med. 1997; 336: 263265.
  • 16
    Ferone D, van Hagen M, van Koetsvald PM,et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology. 1999; 140: 373380.
  • 17
    van Hagen PM, Hofland LJ, ten Bokum AMC,et al. Neuropeptides and their receptors in the immune system. Ann Med. 1999; 31(suppl 2): 15–22.
  • 18
    Wymenga ANM, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999; 17: 11111117.
  • 19
    Masaoka A, Monden Y, Nakahara K, Tahioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48: 24852492.
  • 20
    Rosai J, Sobin LH. Histological typing of tumours of the thymus. World Health Organization, International Histological Classification of Tumours. 2nd ed. Berlin, Heidelberg, New York: Springer Verlag; 1999.
  • 21
    Hu E, Levine J. Chemotherapy of malignant thymoma. Case report and review of the literature. Cancer. 1986;57: 11011104.
  • 22
    Lauriola L, Erlandson RA, Rosai J. Neuroendocrine differentiation is a common feature of thymic carcinoma. Am J Surg Pathol. 1998; 22: 10591066.
  • 23
    Hishima T, Fukayama M, Hayashi Y, Fuji T, Arai K, Shiozawa Y, et al. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma. Hum Pathol. 1998; 29: 330338.
  • 24
    Dardenne M, Itoh T, Homo-Delarche F. Presence of glucocorticoid receptors in cultured thymic epithelial cells. Cell Immunol. 1986; 100: 112.
  • 25
    Dardenne M, Savino W. Neuroendocrine control of the thymic epithelium: modulation of thymic endocrine function, cytokeratin expression and cell proliferation by hormones and neuropeptides. Progr Neuroendocrin Immunol. 1990; 3: 1825.
  • 26
    Suda T, Sugimura S, Hattori Y, et al. High-dose methylprednisolone-containing chemotherapy in advanced invasive thymoma—report of three cases. Nippon Kyobu Geha Gakkai Zasshi. 1998; 46: 115120.
  • 27
    Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996; 334: 246254
  • 28
    Timsit J, Savino W, Safieh B, et al. Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. J Clin Endocrinol Metab. 1992; 75: 183188
  • 29
    de Mello-Coelho V, Gagnerault MC, Souberbielle J-C, et al. Growth hormone and its receptor are expressed in human thymic cells. Endocrinology. 1999; 139: 38373842.
  • 30
    Reubi JC, Waser B, Laissue JA, Gebbers J-O. Somatostatin and vasoactive intestinal peptide receptors in human mes-enchymal tumors: in vitro identification. Cancer Res. 1996; 56: 1922– 1931.
  • 31
    Schultz S, Schultz S, Schmitt J, et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res. 1998; 4: 2047– 2052.
  • 32
    Ingle JN, Suman VJ, Kardinal CG, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast cancer. Cancer. 1999; 85: 12841292.
  • 33
    Kogner P, Borgström P, Bjellerup P, et al. Somatostatin in neuroblastoma and ganglioneuroma. Eur J Cancer. 1997; 33: 20842089.
  • 34
    Witzig TE, Letendre L, Gerstner J, et al. Evaluation of somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group Trial. J Clin Oncol. 1995; 13: 20122015.